<DOC>
	<DOCNO>NCT03006471</DOCNO>
	<brief_summary>Prediabetes define intermediate metabolic state lead development type 2 diabetes mellitus ( DM2 ) prehypertension category assign identify patient risk develop hypertension ( AH ) , pathologies abnormality variation blood pressure ( BP ) relate organ damage , evaluation perform ambulatory blood pressure monitoring ( ABPM ) . Dapagliflozin selective reversible inhibitor sodium-glucose co-transporter type 2 ( SGLT-2 ) , reduce renal reabsorption glucose promote excretion glucose urine , way glucose blood . Another report effect decrease BP , would interest evaluate effect patient prediabetes prehypertension , potential therapy treat disorder prevent progression DM2 HT , respectively . The aim study evaluate effect Dapagliflozin variability blood pressure patient prediabetes prehypertension without pharmacological treatment . The investigator hypothesis administration dapagliflozin decrease variability blood pressure patient prediabetes prehypertension without pharmacological treatment .</brief_summary>
	<brief_title>Effect Dapagliflozin Blood Pressure Variability Prediabetes Prehypertension</brief_title>
	<detailed_description>A randomized , double-blind , placebo-controlled clinical trial 30 patient diagnosis prediabetes prehypertension without treatment . They assign randomly two group 15 patient receive 10 mg Dapagliflozin ( Forxiga , Astra Zeneca ) placebo , one per day breakfast 12 week . There calculate body mass index ( BMI ) ; low-density lipoprotein cholesterol ( LDL-c ) ; very-low density lipoprotein ( VLDL ) , glomerular filtration rate blood pressure variability . This protocol 's already approve local ethic committee write informed consent 's go obtained volunteer . Statistical analysis present measure central tendency dispersion , average deviation standard quantitative variable ; frequency percentages variable qualitative . Qualitative variable analyze X2/ exact fisher test , use difference inter-group Mann-Whitney U Test coefficient variation , Wilcoxon Test index variability within-groups difference . It consider statistical significance p ≤0.05 .</detailed_description>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Prehypertension</mesh_term>
	<criteria>Informed consent sign Patients sex , age 30 60 year Diagnosis prediabetes accord ADA criterion ( fast blood glucose level 100126 mg/dl ; postprandial blood glucose level oral glucose tolerance test 75 oral glucose 140199 mg/dl ; glycosylated hemoglobin 5.76.4 % ) Diagnosis prehypertension accord JNC8 ( Eighth Joint National Committee ) blood pressure 120139/ 8089 mmHg . BMI &gt; 35 kg/m2 Glomerular filtration rate &gt; 60mL/min/1.73m2 Women confirm suspected pregnancy Women lactation and/or puerperium Hypersensibility ingredients intervention Physical impossibility take pill Known uncontrolled renal , hepatic , heart thyroid diseased Diabetes diagnosis Previous treatment glucose blood pressure Triglycerides ≥400 mg/dL Total cholesterol ≥240 mg/dL History cardiovascular disease Worker per shift / night</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prediabetes</keyword>
	<keyword>Prehypertension</keyword>
	<keyword>Variability blood pressure</keyword>
	<keyword>ABPM</keyword>
	<keyword>Dapagliflozin</keyword>
	<keyword>SGLT2</keyword>
</DOC>